Overview

Regulatory Post Marketing Surveillance Study on Nexavar®

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
Details
Lead Sponsor:
Bayer
Treatments:
Sorafenib